BridgeBio publishes acoramidis-versus-tafamidis ATTR-CM analysis presentation

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00
  • BridgeBio Pharma published a placebo-anchored matching-adjusted indirect comparison of acoramidis versus tafamidis 80 mg in transthyretin amyloid cardiomyopathy, using ATTRibute-CM as index trial versus ATTR-ACT as comparator.
  • Analysis showed acoramidis linked to 34% relative risk reduction in cumulative cardiovascular-related hospitalization versus tafamidis over 30 months, with relative risk ratio 0.66 (95% CI 0.46-0.95).
  • All-cause mortality result favored acoramidis but missed statistical significance, with hazard ratio 0.72 (95% CI 0.41-1.26).
  • Safety profile was comparable between treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on May 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.